Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Hold” from Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has been assigned an average rating of “Hold” from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $4.79.

Separately, StockNews.com began coverage on Marinus Pharmaceuticals in a research note on Wednesday. They set a “sell” rating on the stock.

Marinus Pharmaceuticals Price Performance

NASDAQ MRNS opened at $0.55 on Monday. The company has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $9.07. The company’s fifty day moving average price is $0.55 and its two-hundred day moving average price is $0.72.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MRNS. JPMorgan Chase & Co. raised its holdings in shares of Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 126,752 shares during the last quarter. Franklin Resources Inc. boosted its position in Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares during the period. Deltec Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter worth $107,000. Jacobs Levy Equity Management Inc. increased its holdings in shares of Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 117,255 shares during the period. Finally, Suvretta Capital Management LLC raised its stake in shares of Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after purchasing an additional 1,253,901 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.